CompletedPhase 1NCT03502902

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sunshine Lake Pharma Co., Ltd.
Principal Investigator
Irene Mirkin, MD
Covance
Intervention
HEC 68498(drug)
Enrollment
55 enrolled
Eligibility
18-60 years · All sexes
Timeline
2018 – 2019

Study locations (1)

Collaborators

Covance

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03502902 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials